Price T Rowe Associates Inc. MD Buys 2,878 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS)

Price T Rowe Associates Inc. MD raised its stake in Astria Therapeutics, Inc. (NASDAQ:ATXS) by 19.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 17,762 shares of the biotechnology company’s stock after acquiring an additional 2,878 shares during the quarter. Price T Rowe Associates Inc. MD’s holdings in Astria Therapeutics were worth $159,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Teacher Retirement System of Texas bought a new position in shares of Astria Therapeutics in the fourth quarter worth about $91,000. KLP Kapitalforvaltning AS bought a new position in shares of Astria Therapeutics in the fourth quarter worth about $41,000. American Century Companies Inc. lifted its holdings in shares of Astria Therapeutics by 9.9% in the fourth quarter. American Century Companies Inc. now owns 42,693 shares of the biotechnology company’s stock worth $382,000 after acquiring an additional 3,839 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Astria Therapeutics by 1.6% in the fourth quarter. Vanguard Group Inc. now owns 2,677,353 shares of the biotechnology company’s stock worth $23,936,000 after acquiring an additional 41,833 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Astria Therapeutics by 101.7% in the third quarter. JPMorgan Chase & Co. now owns 39,144 shares of the biotechnology company’s stock worth $431,000 after acquiring an additional 19,735 shares during the last quarter. Institutional investors own 98.98% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on ATXS shares. JMP Securities started coverage on shares of Astria Therapeutics in a report on Friday, January 31st. They issued an “outperform” rating and a $26.00 price objective for the company. Wedbush reiterated an “outperform” rating and issued a $28.00 price objective (up previously from $27.00) on shares of Astria Therapeutics in a report on Wednesday, March 12th. Citizens Jmp upgraded shares of Astria Therapeutics to a “strong-buy” rating in a report on Friday, January 31st. HC Wainwright reiterated a “buy” rating and issued a $16.00 price objective on shares of Astria Therapeutics in a report on Tuesday, March 11th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $47.00 price objective on shares of Astria Therapeutics in a report on Wednesday. Six research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $30.00.

Astria Therapeutics Stock Performance

NASDAQ:ATXS opened at $3.96 on Friday. The company has a market capitalization of $223.48 million, a PE ratio of -1.89 and a beta of 0.45. The company has a 50 day simple moving average of $5.01 and a two-hundred day simple moving average of $7.36. Astria Therapeutics, Inc. has a fifty-two week low of $3.56 and a fifty-two week high of $12.92.

Astria Therapeutics (NASDAQ:ATXS) last released its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.10). Research analysts predict that Astria Therapeutics, Inc. will post -1.65 EPS for the current year.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.